Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.

International journal of oncology

Volumn 18, Issue 2, 2001, Pages 383-391

  Mantovani, G ^a   Maccio, A ^a   Madeddu, C ^a   Massa, E ^a   Mudu, M C ^a   Mulas, C ^a   Gramignano, G ^a   Massidda, S ^a   Murgia, V ^a   Lusso, M R ^a   Mura, L ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTIOXIDANT; CYTOKINE; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; RECOMBINANT PROTEIN;

AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOTHERAPY; LUNG TUMOR; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIOXIDANTS; CONFIDENCE INTERVALS; CYTOKINES; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MALE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; QUALITY OF LIFE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 0035256418     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.18.2.383     Document Type: Article

References (0)